Literature DB >> 1542327

Tamoxifen--panacea or Pandora's box?

N E Davidson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1542327     DOI： 10.1056/NEJM199203263261308

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations.

Authors:  M Dayan; H Zinger; F Kalush; G Mor; Y Amir-Zaltzman; F Kohen; Z Sthoeger; E Mozes
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 2.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

3.  Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue.

Authors:  H Pujol; J Girault; P Rouanet; S Fournier; J Grenier; J Simony; J B Fourtillan; J L Pujol
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats.

Authors:  Y P Dragan; S Fahey; K Street; J Vaughan; V C Jordan; H C Pitot
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.